Negative assessment for InSightec
This article was originally published in The Gray Sheet
Executive Summary
BlueCross BlueShield's Technology Evaluation Center says there is insufficient evidence to conclude that the firm's ExAblate 2000 MR-guided, focused ultrasound system improves net health outcomes of patients with symptomatic uterine fibroids. When the device received PMA approval in October 2004, the firm was required to collect postmarket data for three years (1"The Gray Sheet" Oct. 25, 2004, p. 20)...
You may also be interested in...
InSightec ExAblate 2000 Approved For Uterine Fibroids; 3-Year Study Required
FDA approval conditions for InSightec's ExAblate 2000 uterine fibroid ultrasound treatment respond to advisory panel concerns about short-term safety and efficacy data in the original PMA submission
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.